Related references
Note: Only part of the references are listed.Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
Jian Zhao et al.
INVESTIGATIONAL NEW DRUGS (2020)
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Zhiqiang Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis
Haiqi He et al.
THORACIC CANCER (2020)
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.
Jing Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
Wang Jing et al.
CANCER BIOLOGY & THERAPY (2019)
A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).
Min Hee Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.
Bo Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.
Feng Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Camrelizumab: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Hendrik Ungefroren
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
760PPembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181
J Chen et al.
ANNALS OF ONCOLOGY (2019)
526PA phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
L Chu et al.
ANNALS OF ONCOLOGY (2019)
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis
Brian W. Labadie et al.
CLINICAL CANCER RESEARCH (2019)
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
David Vrana et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma
Wenjia Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
Shuhei Mayanagi et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2019)
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
T. Ruhstaller et al.
ANNALS OF ONCOLOGY (2018)
Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target
Shaohua Ma et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
Toxicities Associated With PD-1/PD-L1 Blockade
Daniel Y. Wang et al.
CANCER JOURNAL (2018)
Randomised phase III trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer
Shi-Xiu Wu et al.
EUROPEAN JOURNAL OF CANCER (2018)
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial
Gilberto de Castro Junior et al.
EUROPEAN JOURNAL OF CANCER (2018)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Zaima Mazorra et al.
SEMINARS IN ONCOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909).
Yoshinori Ito et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
642PPhase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1
C-C Lin et al.
ANNALS OF ONCOLOGY (2018)
Risk factors for oesophageal cancer
Shao-Hua Xie et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials
Ze-Hao Huang et al.
BMC CANCER (2018)
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients with Esophageal Squamous Cell Cancer
Z. Jing et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
LAG-3: a very singular immune checkpoint
Yuan Lui et al.
NATURE IMMUNOLOGY (2018)
Immunogenic effects of chemotherapy-induced tumor cell death
Yi-Jun Wang et al.
GENES & DISEASES (2018)
Immunotherapy for esophageal squamous cell carcinoma : a review
Kosaku Mimura et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2018)
Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer.
Thomas Benjamin Karasic et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
Yu Zhang et al.
JOURNAL OF CANCER (2018)
Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial
A. M. Horgan et al.
DISEASES OF THE ESOPHAGUS (2017)
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D. Petty et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Jin Zhou et al.
NATURE COMMUNICATIONS (2017)
High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients
Qi Song et al.
ONCOTARGET (2017)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Caroline Jochems et al.
ONCOTARGET (2017)
Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial
Mohan Suntharalingam et al.
JAMA ONCOLOGY (2017)
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis
T. Song et al.
DISEASES OF THE ESOPHAGUS (2017)
Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for unresectable esophageal squamous cell carcinoma: Long term follow-up of survival in a phase II study.
Xiaodong Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis
Hai-De Qin et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
F. Klevebro et al.
ANNALS OF ONCOLOGY (2016)
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Lordick et al.
ANNALS OF ONCOLOGY (2016)
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
Emil ter Veer et al.
CANCER AND METASTASIS REVIEWS (2016)
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
Ming Lu et al.
CANCER SCIENCE (2016)
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
S. H. Lim et al.
EUROPEAN JOURNAL OF CANCER (2016)
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
Gerard Lledo et al.
EUROPEAN JOURNAL OF CANCER (2016)
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada et al.
GASTROENTEROLOGY (2016)
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis
Emil ter Veer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis
Jianxiang Song et al.
ONCOTARGETS AND THERAPY (2016)
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
Chuanhua Zhao et al.
ONCOTARGET (2016)
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis
Emil ter Veer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Therapeutic peptide vaccince therapy in combination with CpG-B for the patients with advanced esophageal squamous cell carcinoma.
Masahiro Katsuda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
Ling Zhang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
Diet and Upper Gastrointestinal Malignancies
Christian C. Abnet et al.
GASTROENTEROLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study
Yaping Xu et al.
ONCOTARGET (2015)
Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials
D. P. S. Sohal et al.
DISEASES OF THE ESOPHAGUS (2015)
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
Yelena Y. Janjigian et al.
PLOS ONE (2015)
Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
Hisae Iinuma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy et al.
LANCET ONCOLOGY (2014)
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J. Dutton et al.
LANCET ONCOLOGY (2014)
Identification of genomic alterations in oesophageal squamous cell cancer
Yongmei Song et al.
NATURE (2014)
Genetic landscape of esophageal squamous cell carcinoma
Yi-Bo Gao et al.
NATURE GENETICS (2014)
Genomic and molecular characterization of esophageal squamous cell carcinoma
De-Chen Lin et al.
NATURE GENETICS (2014)
Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway
Xiaoming Xu et al.
PLOS ONE (2014)
LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).
Dirk Rades et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
N. C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2013)
Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)
Kenichi Nakamura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby et al.
LANCET ONCOLOGY (2013)
Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial
Renuka Iyer et al.
ONCOLOGY (2013)
Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail
Xue Meng et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Epidemiology of esophageal cancer
Yuwei Zhang
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma
Qifeng Wang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
Jun Liang et al.
ONCOTARGETS AND THERAPY (2013)
Comparative Genomics of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
Santhoshi Bandla et al.
ANNALS OF THORACIC SURGERY (2012)
Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma
Yongshun Chen et al.
CANCER SCIENCE (2012)
Regulation of TGFβ in the immune system: An emerging role for integrins and dendritic cells
John J. Worthington et al.
IMMUNOBIOLOGY (2012)
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
David J. Adelstein et al.
INVESTIGATIONAL NEW DRUGS (2012)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
Koji Kono et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
F. De Vita et al.
BRITISH JOURNAL OF CANCER (2011)
A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus
David H. Ilson et al.
CANCER (2011)
PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
Ken Kato et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
Thomas Ruhstaller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma
Young Mog Shim et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Joel Tepper et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells
Yun Ling et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences
Olivier Dassonville et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
M Stahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
